[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-357015-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-357015-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prevalence-of-recurrent-and-non-recurrent-brca1-and-brca2-pathogenic-variants-in-polish-breast-cancer-patients-insights-from-a-regional-genetic-testing-cohort-from-lower-silesia","Prevalence of recurrent and non-recurrent BRCA1 and BRCA2 pathogenic variants in Polish breast cancer patients - insights from a regional genetic testing cohort from Lower Silesia","","Prevalence and variant spectra of BRCA1/2 pathogenic and likely pathogenic variants (PVs/LPVs) differ across populations, motivating region-specific analyses to determine which variants are recurrent and to assess diagnostic strategies. This study reports the first comprehensive BRCA testing analysis from Central Europe using a Lower Silesia (Poland) cohort. Next-generation sequencing was performed on 1,021 consecutive breast cancer patients, comparing clinical and pathological features between PV/LPV carriers and non-carriers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prevalence-of-recurrent-and-non-recurrent-brca1-and-brca2-pathogenic-variants-in-polish-breast-cancer-patients-insights-from-a-regional-genetic-testing-cohort-from-lower-silesia/357015/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prevalence-of-recurrent-and-non-recurrent-brca1-and-brca2-pathogenic-variants-in-polish-breast-cancer-patients-insights-from-a-regional-genetic-testing-cohort-from-lower-silesia/357015.png","ImageObject",300,407,{"name":42,"@type":43},"Mabel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about BRCA1/2 variants?","Question",{"text":63,"@type":64},"It examines how common recurrent and non-recurrent BRCA1/2 pathogenic variants are in Polish breast cancer patients and how these findings reflect diagnostic and population differences.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the BRCA1/2 testing performed in this research?",{"text":68,"@type":64},"BRCA1/2 was analyzed using next-generation sequencing (NGS) in a regional cohort of 1,021 consecutive breast cancer patients from Lower Silesia.",{"name":70,"@type":61,"acceptedAnswer":71},"What main differences were observed between PV/LPV carriers and non-carriers?",{"text":72,"@type":64},"Carriers were younger at diagnosis and showed a distinct tumor phenotype, including a higher prevalence of triple-negative breast cancer, differences in ER/PR expression, higher Ki-67, larger tumor size, and more advanced stage at diagnosis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},357015,1790214096,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","Matkowski et al. BMC Cancer (2026) 26:714 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16017-y](https://doi.org/10.1186/s12885-026-16017-y)  \nRESEARCH Open Access  \nPrevalence of recurrent and non-recurrent BRCA1 and BRCA2 pathogenic variants in Polish breast cancer patients: insights from a regional genetic testing cohort from Lower Silesia  \nRafal Matkowski 1,2*, Mariola Abrahamowska1,2, Dagmara Michalowska1, Agnieszka Chrusciel1,  \nJolanta Szelachowska1,2, Dorota Blomka 1, Paulina Lawicka 1, Ewelina Czykalko1, Aleksandra Pietron 1, Marcin Ekiert 1,2, Anna Doraczynska-Kowalik3, Gabriela Janus-Szymanska5, Piotr Kasprzak1, Bartlomiej Szynglarewicz1,2 and Izabela Laczmanska4  \nAbstract  \nBackground The prevalence and spectrum of pathogenic and likely pathogenic variants (PVs/LPVs) in BRCA1/2 vary across populations, necessitating region-specific analyses to identify recurrent and non-recurrent variants and to evaluate the effectiveness of current diagnostic strategies. Published experience remains dominated by North American and West-European or Nordic cohorts. To address this gap, we present the first comprehensive analysis of BRCA testing outcomes from Central Europe.  \nMethods A next-generation sequencing (NGS) analysis of BRCA1/2 was performed in a regional cohort of 1,021 consecutive breast cancer patients from Lower Silesia (Poland), treated between March 2024 and April 2025. Clinical and pathological characteristics were compared between PV/LPV carriers and non-carriers.  \nResults Nineteen distinct PVs/LPVs (11 in BRCA1 and 8 in BRCA2) were identified in 30 patients (2 . 94%; 95% CI: 2. 07%– 4. 16%, Wilson) . The most frequent variant was BRCA1 c. 5266dup (30% of all variants), followed by c. 181T >G (10%) . Most variants (56 . 7%) were unique. No copy number variants were detected. Carriers were significantly younger at diagnosis (median 47 vs. 66 years; p \u003C 0. 0001) and exhibited a distinct tumor phenotype, including a markedly higher prevalence of triple-negative breast cancer (43 . 3% vs. 8. 5%; OR = 8 . 24; p \u003C 0. 0001), lower ER/PR expression, higher Ki-67, larger tumor size, and more advanced stage at diagnosis (all p \u003C 0. 05) .  \nConclusions The prevalence of BRCA1/2 PVs/LPVs in this unselected Polish regional cohort was lower than previously reported, with a high proportion of non-recurrent variants. This Central European cohort demonstrates results consistent with international benchmarks. Our findings suggest limited effectiveness of founder mutation–based  \n*Correspondence:  \nRafal Matkowski[rafal.matkowski@umw.edu.pl](rafal.matkowski@umw.edu.pl)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nMatkowski et al. BMC Cancer (2026) 26:714 Page 2 of 11  \ntesting strategies and support the implementation of comprehensive NGS-based diagnostics in routine clinica","cbCaivSY1PpfjwbR","https://ap.wps.com/l/cbCaivSY1PpfjwbR","pdf",1238840,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Genetic testing in breast cancer\n## Molecular profiling and hereditary risk\n# Methods\n# Results\n# Discussion","[{\"question\":\"What question does the study address about BRCA1/2 variants?\",\"answer\":\"It examines how common recurrent and non-recurrent BRCA1/2 pathogenic variants are in Polish breast cancer patients and how these findings reflect diagnostic and population differences.\"},{\"question\":\"How was the BRCA1/2 testing performed in this research?\",\"answer\":\"BRCA1/2 was analyzed using next-generation sequencing (NGS) in a regional cohort of 1,021 consecutive breast cancer patients from Lower Silesia.\"},{\"question\":\"What main differences were observed between PV/LPV carriers and non-carriers?\",\"answer\":\"Carriers were younger at diagnosis and showed a distinct tumor phenotype, including a higher prevalence of triple-negative breast cancer, differences in ER/PR expression, higher Ki-67, larger tumor size, and more advanced stage at diagnosis.\"}]","Prevalence of recurrent and non-recurrent BRCA1 and BRCA2 pathogenic variants in Polish breast cancer patients - insights from a regional genetic testing cohort from Lower Silesia | PDF",1790128618,28,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/346f2153bb91d80f93fa5387bd9e0511.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6b6fc4403d5cab2307262d985113666.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e3b0cf2e7a20dbb8226f9bcbceca14bc.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e7fa32f55bbdabb150dfcf6d960ae49.webp",980,1306]